SHARED RESOURCE MANAGEMENT The Lineberger Comprehensive Cancer Center has a strong history of providing high quality and cost-effective shared resources that offer innovative services and technologies to the membership. The oversight of the SRs involves the Director, Deputy Director, and Associate Directors of the Center. Program leaders also provide valuable input and guidance on the services offered. Center members provide feedback through surveys and serve on SR active internal advisory boards for each SR. Over the last five years, this management process has provided substantial new infrastructure for the faculty including: 1) an expanded and more robust tissue- based research pipeline for correlative work, 2) new technologies such as single cell analysis, mass spec cytometer instrumentation, and a CyroEM, 3) expanded faculty SR leadership expertise in pathology and biostatistics. The financial and administrative oversight is provided by the Associate Director of Administration and his staff of 4 FTEs devoted to this endeavor. The SRs are well managed and are well used as demonstrated by these statistics: ? 97% of 2018 user-survey respondents stated the SR overall experience was excellent or good. ? 81% of LCCC Members used a Shared Resource in FY19 ? 82% of FY19 total LCCC managed-Shared Resource users were Center faculty Importantly, the SRs are cost-effective and provide exceptional value to the members. The Center requests 8% of the operating budget for the SRs from the CCSG. This is greatly leveraged through a sustained annual institutional commitment of over $10M in operational support, 37% of the total SR operating budget. The remaining SR operating budget, approximately $14.3M, is recovered by recharge mechanisms. As a result of the CCSG and institutional commitment, members receive discounts on fees, priority access and free consultative services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089825
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications